Cardiac device-maker Medtronic and dialysis-provider DaVita Healthcare Partners plan to team up to identify and study cardiac arrhythmia in patients undergoing dialysis.
Home hemodialysis device maker NxStage Medical touts a new study showing that kidney patients who underwent frequent home hemodialysis had a better quality of life and lower risk of death than those who underwent peritoneal dialysis.
Astute Medical is in line to receive up to $30 million from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test.
Astute Medical said it's in line to receive up to $30 million under a standing loan agreement from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test, and could receive an additional $10 million if it hits certain revenue milestones.
Another trial of Medtronic's Symplicity renal denervation device in treating hypertension shows no benefit compared with a sham procedure.
New data from CardioMEMs CHAMPION clinical trial shows that the company's implanted pulmonary artery pressure monitor helps reduce heart failure hospitalizations without compromising kidney function in patients with renal failure.
St. Jude Medical (NYSE:STJ) subsidiary CardioMEMs touted new study results this week showing that its implanted heart monitor is safe and effective in patients with chronic kidney disease.
Is renal denervation for hypertension dead or alive? Experts agree that more studies are needed.
The efficacy of renal denervation is in doubt and should be confirmed or ruled out in treating resistant hypertension, according to an expert panel in a debate over the once high-flying technology at the Transcatheter Cardiovascular Therapeutics conference in Washington.
Medtronic's failed Symplicity HTN-3 renal denervation study doesn't look any better with 12 months of follow-up, according to new results presented at this year's European Society of Cardiology Congress.
Renal denervation technologies took another blow this week as 1-year results from Medtronic's (NYSE:MDT) much-lamented Symplicity HTN-3 trial still turned out no signs that the treatment is effective against hypertension.